ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Educational Symposium

IgA Nephropathy: The Role of the Renal Endothelin System and Other Therapeutic Implications

November 03, 2022 | 12:45 PM - 01:45 PM

Location: Regency Ballroom R, Hyatt Regency Orlando

Session Description

IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide and remains an important cause of ESKD. Owing to the complexity of disease mechanisms, significant heterogeneity in clinical presentation and renal pathological features, and limitations in trial design and execution, the development of personalized, effective, and safe therapies to prevent or delay disease progression in patients with IgAN has been a difficult task. Recent studies evaluating the efficacy of immunosuppressive therapies in high-risk patients have yielded mixed results and demonstrated substantial adverse effects associated with immunosuppression.

Despite significant challenges, increased understanding of the multi-hit pathogenesis of IgAN has led to discovery of novel therapeutic targets. One such target is endothelin 1, which, via its action on the endothelin A receptor, has been implicated in glomerular injury in IgAN and is an important driver for proteinuria, subsequent tubulointerstitial injury/fibrosis, and ultimately progressive decline in kidney function. The potential benefit of endothelin receptor antagonists and other emerging therapies is currently being evaluated in several clinical trials in IgAN, using proteinuria reduction as surrogate end point for long-term kidney survival.

In this symposium, experts in glomerular diseases address the clinical implications of proteinuria in IgAN, provide new insights into the pathogenesis of IgAN including the role of the renal endothelin system, and discuss emerging therapeutic options for IgAN.

Support is provided by an educational grant from Travere Therapeutics, Inc.

Learning Objective(s)

  • State the significance of proteinuria reduction in IgAN
  • Describe the role of endothelin 1 in IgAN and its therapeutic implications
  • Discuss other emerging therapies in IgAN

Learning Pathway(s)

  • Glomerular Diseases

Moderator

  • Tingting Li, MD, MSc, FASN

Presentations

  • Introduction
    12:45 PM - 12:55 PM
    Tingting Li, MD, MSc, FASN
  • Proteinuria in IgA Nephropathy: Mechanisms and Clinical Implications
    12:55 PM - 01:15 PM
    Jonathan Barratt, MBChB, PhD
  • Emerging Therapies in IgA Nephropathy: Targeting the Renal Endothelin System and Other Therapies
    01:15 PM - 01:35 PM
    Richard A. Lafayette, MD
  • Questions and Answers
    01:35 PM - 01:45 PM